
    
      OUTLINE:

      Patients receive astatine At 211 anti-CD45 monoclonal antibody BC8-B10 intravenously (IV) on
      any day between days -10 and -7, fludarabine IV on days -6 to -2, cyclophosphamide IV over 1
      hour on days -6 to -5 and 3 to 4, and thymoglobulin IV over 4-6 hours on days -4 to -2.
      Patients undergo TBI on day -1 and hematopoietic cell transplant on day 0. Beginning day 5,
      patients also receive mycophenolate mofetil orally (PO) or IV thrice daily every 8 hours up
      to day 35 if no GVHD present and sirolimus PO daily until day 365.

      After completion of study treatment, patients are followed up at 1 and 2 years and then
      periodically for up to 5 years.
    
  